Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Featured Articles

Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer

Makoto Ishikawa, Joji Kitayama and Hirokazu Nagawa
Makoto Ishikawa
Department of Surgery, Division of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joji Kitayama
Department of Surgery, Division of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirokazu Nagawa
Department of Surgery, Division of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-03-0749 Published July 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: To evaluate leptin and leptin receptor (OB-R) expression in human breast cancer and determine whether it could be effective for the prevention and treatment of breast cancer.

Experimental Design: Immunohistochemical staining using specific antibodies was used to evaluate the protein expression of leptin and OB-R in 76 invasive ductal carcinomas and 32 samples of corresponding normal mammary gland, and the relationship between the expression of OB-R and leptin and clinicopathological features was analyzed.

Results: Normal mammary epithelial cells did not express a significant level of Ob-R, whereas carcinoma cells showed positive staining for OB-R in 63 (83%) cases. Both normal epithelial cells and carcinoma cells expressed a significant level of leptin. However, overexpression of leptin, as determined by staining intensity, was observed in 70 cancers (92%) but in no normal epithelium. The expression of OB-R showed a significant correlation with the level of leptin expression. Interestingly, distant metastasis was detected in 21 (34%) of 61 OB-R-positive tumors with leptin overexpression, but in none of the 15 tumors that lacked OB-R expression or leptin overexpression (P < 0.05). Consequently, patients with the former tumors showed significantly lower survival than those with the latter.

Conclusions: Leptin may have a promoting effect on the carcinogenesis and metastasis of breast cancer, possibly in an autocrine manner. Functional inhibition of leptin may be effective for the prevention and treatment of breast cancer.

INTRODUCTION

The adipocyte-derived cytokine, leptin, is thought to play a key role in the control of satiety, energy expenditure, food intake, and various reproductive processes (1, 2, 3) . Leptin has 167 amino acids with a molecular mass of 16 kDa and is produced mainly by adipocytes (4) . The plasma leptin level is representative of body fat mass (5, 6, 7, 8) and increases in a logarithmic fashion with an increase in body mass in mice (9) . Additionally, leptin has been shown to control metabolism by affecting the metabolic, neuroendocrine, reproductive, and hematopoietic systems (10) . Although initially thought to be exclusively expressed in and secreted by adipocytes, leptin has been identified in additional tissues, such as placenta (11) , gastric (12) and colonic mucosa (13) , as well as mammary epithelial cells (14) .

Leptin exerts its physiological action through the leptin receptor (OB-R), a member of the cytokine family of receptors. OB-R was initially identified in the brain, which explained the negative feedback mechanism of controlling food intake and body weight (15) . Further studies, however, have demonstrated that OB-R is also expressed in many other tissues, including brain, placenta, pancreas, adrenal gland, hematopoietic cells, liver, lung, and heart (11 , 13 , 16, 17, 18, 19, 20, 21, 22) . OB-R has also been identified in malignant cells of diverse origins, including lung and gastric carcinomas and leukemic cells (22, 23, 24) . In addition, leptin can regulate the proliferation and invasiveness of colonic and renal epithelial cells (13 , 25) , and the expression of leptin in pituitary adenomas showed a positive correlation with the invasiveness of tumors (26) . However, the expression of OB-R in various cancers has not been fully investigated, and the precise role of leptin in the development and promotion of cancer remains unknown.

Recently, increased body weight has been shown to be associated with increased death rates for cancers at multiple specific sites (27) . Previous studies have consistently shown a positive association between adiposity and increased risk of cancer of the endometrium, kidney, colon, and gallbladder in women, and breast cancer in postmenopausal women (28, 29, 30, 31, 32, 33, 34) . These results encouraged us to evaluate the expression of leptin and its receptor in breast cancers because leptin plays a major role in the regulation of weight and adiposity. In this study, we characterized the expression pattern of leptin and OB-R in breast cancer specimens by immunohistochemical study, and delineated the possible role of this cytokine in the tumorigenesis and spread of breast cancer.

MATERIALS AND METHODS

Patients and Materials.

Seventy-six cases of invasive ductal carcinoma, which was surgically resected in the Department of Surgery, The University of Tokyo, from 1992 to 1999, were included in this study. In all cases, ipsilateral axillary lymph node dissection was performed. In all cases, serial-step sections 3-mm wide were cut, fixed in 10% formalin solution, then embedded in paraffin. All of the resected primary tumors and regional lymph nodes were stained with H&E and histologically examined according to the International Union Against Cancer Tumor-Node-Metastasis classification (35) . Several discrete histological parameters, including lymphatic invasion, venous invasion, and lymph node metastasis, were additionally examined. The outcome of these patients was followed up for 3–10 years (mean 5.2 years).

Immunohistochemical Study of OB-R and Leptin.

The expression of OB-R and leptin was investigated by immunohistochemical staining using affinity-purified goat polyclonal antibodies against OB-R (M-18; Santa Cruz Biotechnology, Santa Cruz, CA; Ref. 13 and 22 ) and rabbit polyclonal antibodies against leptin (A20; Santa Cruz Biotechnology; Ref. 13 and 22 ), respectively. Sections (3-μm thick) were deparaffinized in xylene, hydrated through a graded series of ethanol, and heated in a microwave oven for two 7-min cycles (500 W). After rinsing in PBS, endogenous peroxidase activity was inhibited by incubation with 0.3% hydrogen peroxide in 100% methanol for 30 min. After three washes in PBS, nonspecific reaction was blocked by incubation with PBS containing 5% skimmed milk for 30 min at room temperature, and then the sections were incubated with normal rabbit or goat serum for 30 min. The sections were incubated overnight at 4°C in humid chambers with the primary antibody to leptin at 1:70 dilution or to OB-R at 1:100. After three washes in PBS, the sections were incubated with biotinylated rabbit antigoat or rabbit immunoglobulin for 30 min. After washing again with PBS, the slides were treated with peroxidase-conjugated streptavidin for 30 min, and developed by immersion in 0.01% H2O2 and 0.05% diaminobenzidine tetrahydrochloride for 3 min, followed by light counterstaining with Mayer’s hematoxylin. Assessment of immunoreactivity was performed by two evaluators without knowledge of the background features. In cases with leptin staining, the samples were subdivided into two groups according to their immunoreactivity. When both investigators agreed that the staining intensity of normal epithelial or carcinoma cells was apparently less than that of adipocytes, those tumors were categorized as having low expression, and when cells were stained at a similar level or more strongly than adipocytes, those tumors were categorized as having high expression.

Statistical Analysis.

All statistical calculations were carried out using StatView-J 5.0 statistical software (SAS Institute). The relationship between the expression of OB-R and leptin and clinicopathological features was examined by Student’s t test, Kruskal-Wallis test, and Spearman rank correlation. Differences with a P value < 0.05 were considered to be statistically significant.

RESULTS

Immunohistochemical Detection of OB-R and Leptin.

The expression of leptin and OB-R was evaluated in 76 invasive ductal carcinomas and 32 samples of adjacent normal mammary gland and is summarized in Table 1⇓ . Leptin was positively stained in all of the carcinoma cells and normal mammary epithelial cells (Fig. 1, A–C)⇓ . In these samples, the cytoplasm of epithelial and carcinoma cells was homogeneously stained, and heterogeneity was rarely observed. However, the expression level showed a significant difference between normal and carcinoma cells. In all of the 32 cases, the staining level of leptin was markedly weaker in normal epithelial cells than in adipocytes in adjacent adipose tissue of the same sample (Fig. 1A)⇓ . However, in 70 (92%) cases of breast cancer, most of the carcinoma cells were stained as strongly as adipocytes (Fig. 1C)⇓ . In the other six cases, the staining intensity of carcinoma cells was similar to that of normal epithelium and markedly less than that of adipocytes (Fig. 1B)⇓ . These staining intensities were classified as strong and weak expression of leptin, respectively. From these results, it is presumed that leptin production is enhanced in the majority of breast cancers.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Immunohistochemical staining of leptin (A–C) and Ob-R (D–F). Staining of leptin was very weak in normal epithelial cells (A). Most of the carcinoma cells were stained as strongly as adipocytes (C). In some cases, the staining intensity of carcinoma cells was weak (B). Normal mammary glands showed no significant immunoreactivity for OB-R (D). OB-R was expressed in most of the carcinoma cells (F), but was not expressed in some cases (E).

View this table:
  • View inline
  • View popup
Table 1

Expression of Ob-Ra and leptin in breast carcinoma and normal mammary gland

In contrast to leptin, none of the normal mammary glands showed significant immunoreactivity for OB-R (Fig. 1D)⇓ , whereas OB-R was expressed in most of the carcinoma cells in 63 (83%) carcinomas (Fig. 1F)⇓ . In these carcinoma cells, OB-R could be detected in the cytoplasm as well as the cell membrane but not in the nucleus. Some interstitial cells were positively stained, but the signals were not as strong as those of carcinoma cells. The staining pattern was similar to that in the gastric or colonic epithelium in previous reports (13 , 23) . However, in the other 13 cases, most of the carcinoma cells were negative for OB-R, with only a few tumor cells showing faint staining, and thus these were distinguished as OB-R-negative tumors (Fig. 1E)⇓ .

Relation between Expression of Leptin or OB-R and Clinicopathological Features.

The relation between leptin/OB-R expression and clinicopathological data are shown in Table 2⇓ . The expression levels of both leptin and OB-R tended to increase as tumor size or TMN stage increased, although the relation was not significant. Interestingly, in the 63 OB-R-positive tumors, hematogenous metastasis was detected preoperatively in 4 (6.3%) patients, and 17 (27.0%) patients developed recurrence in distant organs during the follow-up period of 1–8 years. On the contrary, none of the 13 patients with OB-R-negative tumors was associated with distant metastasis, and this difference was statistically significant (P < 0.05). Similarly, distant metastasis was detected in 30% (21 of 70) of tumors with strong leptin expression, but in none of the six tumors with weak leptin expression. However, the expression of leptin or OB-R showed no significant correlation with lymphatic invasion, lymph node metastasis, or levels of the following tumor markers, estrogen receptor and progesterone receptor expression, tumor size, and pathological type.

View this table:
  • View inline
  • View popup
Table 2

The expression of leptin and Ob-R and the clinicopathological characteristics of patients

The relationship between the expression patterns of OB-R and leptin is presented in Table 3⇓ . Of 63 carcinomas with positive OB-R expression, 61 also expressed leptin strongly, whereas only 2 carcinomas (3.2%) expressed leptin weakly. Of the 13 carcinomas that lacked OB-R expression, 4 (31%) expressed leptin weakly. Hence, the expression of leptin and OB-R in breast cancer was significantly correlated (P < 0.01).

View this table:
  • View inline
  • View popup
Table 3

Relationship between the expression of Ob-Ra and leptin

The survival rates of these patients are presented in Fig. 2⇓ . All of the 13 patients with OB-R-negative tumors were alive without recurrence of breast cancer at the end of the observation period. Similarly, all 6 patients with low expression of leptin were alive and free from tumor recurrence. In contrast, 10 of 61 patients who had tumors with positive OB-R and enhanced leptin expression died of breast cancer within 7 years. According to this result, breast cancers with and without overexpression of leptin and OB-R were categorized as high- and low-risk groups for tumor recurrence, respectively.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Survival rate of patients with breast carcinoma in high risk group and low risk group.

DISCUSSION

Epidemiological studies have shown that obesity is a risk factor for breast cancer in postmenopausal women (32, 33, 34) . High levels of serum insulin and estrogen, derived from increased adipose tissue, are considered to contribute to the pathogenesis of breast cancer in those obese patients. However, because circulating leptin is an essential factor regulating fat metabolism, it can be hypothesized that leptin itself might be involved in the development of breast cancer. In fact, serum leptin levels have been shown to be significantly elevated in breast cancer patients compared with controls (36 , 37) , although not in premenopausal patients (38) .

Therefore, we first examined leptin receptor expression in breast cancer tissues. Thus far, six isoforms derived from OB-R transcription have been identified, and a long isoform, OB-Rb, is reported to be responsible for signal transduction (39) . In this study, we used a polyclonal antibody that specifically reacts with OB-Rb (13 , 23) and performed immunostaining of human breast cancers. Our experiments clearly recognized cytoplasmic as well as membranous expression of functional leptin receptor (OB-R) in most of the breast carcinoma cells but not in normal epithelium. Recent studies have shown positive expression of OB-R in human normal or malignant breast epithelial cell lines and that leptin can stimulate the proliferation of both normal and malignant breast epithelial cells (40 , 41) . This is inconsistent with our finding of negative expression of OB-R in normal epithelium. In the study by Hu et al. (41) , normal gland-derived HBL100 cells also expressed OB-R and responded to leptin. Although this cell line was established from maternal milk, it is uncertain whether normal mammary epithelial cells express a significant level of OB-R, because long-term culture might alter the protein expression pattern. However the growth-stimulating effect of leptin on HBL100 was much less than that on a breast cancer cell line, T-47D. This result, together with our data, suggests that the expression of OB-R is induced during the tumorigenesis of breast cancer.

In contrast to OB-R, leptin was positive in both normal epithelial and carcinoma cells. However, the expression of leptin was significantly stronger in carcinoma than in normal epithelium as judged by its staining intensity. The expression of leptin in normal and malignant mammary glands has been reported at the mRNA level (14 , 42) . O’Brien et al. (42) reported that leptin mRNA expression was found to be higher in three different breast cancer cell lines (MCF-7, T470, and MDAMB 231) than in adipose tissue. This finding agrees with our result and suggests enhanced leptin production by the epithelium of mammary glands during tumorigenesis. The relationship between obesity and breast cancer susceptibility has been long verified in mouse experiments (43 , 44) . Recently, Clear et al. (45) have shown a direct contribution of leptin to the development of mammary tumors in a transforming growth factor-α-transgenic and leptin-deficient mouse model. Our data are consistent with these in vivo results as well as previous epidemiological studies and strongly support the positive contribution of leptin to the development of breast cancer.

Another important finding in this study is that the expression levels of leptin and OB-R were correlated with distant metastasis. A significant percentage of OB-R-positive tumors showed hematogenous metastasis or recurrence in distant organs within 5 years, and all of the tumors were categorized as having high leptin expression, whereas no tumor that lacked OB-R expression and up-regulation of leptin expression was associated with distant metastasis. Consistently, patients with OB-R-negative and low leptin-expressing tumors showed an extremely good outcome, and the survival rate tended to be lower for patients with OB-R-positive or high leptin-expressing tumors. Although our data on a small sample size are preliminary in nature, this finding strongly suggests that the leptin signal may be involved in the metastatic process as well as carcinogenesis of breast cancer.

Thus far, there is no definite proof on the role of leptin in cancer metastasis. However, leptin has been reported to stimulate proliferation, an essential element for tumor metastasis, in many cancer cells including breast cancer (41 , 46, 47, 48, 49) . Furthermore, leptin has been shown to promote invasiveness of renal and colonic epithelial cells via phosphatidylinositol 3′-kinase-, rho-dependent, and rac-dependent cascades (13 , 25) . Others have also reported that leptin can augment matrix metalloproteinase production in trophoblasts and endothelial cells (50, 51, 52) , although this has not been reported in cancer cells. In addition, an epidemiological study has also indicated that breast cancer in obese women is more aggressive, with a poor prognosis (53) . These facts, together with our results, support the possibility that the leptin-OB-R signal can play positive roles in breast cancer metastasis. A recent study by Coskun et al. (54) , however, has shown that serum leptin levels are similar in patients with metastatic and non-metastatic breast cancer. This may rather suggest that leptin functions in an autocrine manner at the tumor site to support the development of metastasis of breast cancer.

In addition, the circulating leptin level is observed to increase during pregnancy in humans and mice (55, 56, 57) . Pregnancy-associated breast cancer tends to be found at an advanced stage having a poor prognosis, although the tumors often lack estrogen receptors (58 , 59) . These facts suggest the possibility that leptin may have an important role especially in the pathophysiology of pregnancy-associated breast cancer. Functional inhibition of the leptin signal may be a hopeful strategy for the prevention and treatment of breast cancer.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Requests for reprints: Makoto Ishikawa, Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-3815-5411, Ext. 33246; Fax: 81-3-3811-6822; E-mail: makoto-ishi{at}umin.ac.jp

  • Received December 16, 2003.
  • Revision received March 23, 2004.
  • Accepted March 25, 2004.

References

  1. ↵
    Collins S, Kuhn C, Petro AE, Swick AG, Chrunyk BA, Surwit RS Role of leptin in fat regulation. Nature (Lond), 380: 677 1996.
    OpenUrlCrossRefPubMed
  2. ↵
    Lindheim SR, Sauer MV, Carmina E, Chan PL, Zimmerman R, Lobo RA Circulating leptin levels during ovulation induction: relation to adiposity and ovarian morphology. Fertil Steril, 73: 493-8, 2000.
    OpenUrlCrossRefPubMed
  3. ↵
    Henson MC, Castracane VD Leptin in pregnancy. Biol Reprod, 63: 1219-28, 2000.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Zhang Y, Proenca R, Maffei M, Barone M, Friedman JM Positional cloning of the mouse obese gene and its human homologue. Nature (Lond), 372: 425-32, 1994.
    OpenUrlCrossRefPubMed
  5. ↵
    Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV Leptin: the tale of an obesity gene. Diabetes, 45: 1455-62, 1996.
    OpenUrlFREE Full Text
  6. ↵
    Caro JF Leptin: from 1958 to the present. Can J Diabetes Care, 22: 18-23, 1998.
    OpenUrl
  7. ↵
    Flier JS, Flier EM Obesity and the hypothalamus: novel peptides for new pathways. Cell, 92: 437-40, 1998.
    OpenUrlCrossRefPubMed
  8. ↵
    Dagogo-Jack S, Fanelli C, Paramore D, Brothers C, Landt M Plasma leptin and insulin relationship in obese and nonobese humans. Diabetes, 45: 695-8, 1996.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Smith FJ, Rivera I, Tanenbaum R, Smith W, Campfiel LA Weight loss reverses decreased sensitivity to exogenous ob protein (leptin) in diet induced obese mice. Int J Obes, 22(Suppl 3): 41 1998.
    OpenUrl
  10. ↵
    Ganong WF . Review of medical physiology, 18th edition 223 Appleton and Lange New York 1997.
  11. ↵
    Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P, Mercer JG Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci USA, 94: 11073-8, 1997.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Bado A, Levasseur S, Attoub S, et al The stomach is a source of leptin. Nature (Lond), 394: 790-3, 1998.
    OpenUrlCrossRefPubMed
  13. ↵
    Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP Leptin is a growth factor for colonic epithelial cells. Gastroenterology, 121: 79-90, 2001.
    OpenUrlCrossRefPubMed
  14. ↵
    Smith-Kirwin SM, O’Connor DM, De Johnston J, Lancey ED, et al Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab, 83: 1810-3, 1998.
    OpenUrlCrossRefPubMed
  15. ↵
    Malik KF, Young WS, 3rd Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice. Endocrinology, 137: 1497-500, 1996.
    OpenUrlCrossRefPubMed
  16. ↵
    Cioffi JA, Shafer AW, Zupancic TJ, et al Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med, 2: 585-9, 1996.
    OpenUrlCrossRefPubMed
  17. ↵
    Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M Expression of the functional leptin receptor mRNA in pancreatic islet and direct inhibitory action of leptin on insulin secretion. Diabetes, 46: 313-6, 1997.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Glasow A, Haidan A, Hilbers U, et al Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. J Clin Endocrinol Metab, 83: 4459-66, 1998.
    OpenUrlCrossRefPubMed
  19. ↵
    Briscoe CP, Hanif S, Arch JR, Tadayyon M Leptin receptor long-form signaling in a human liver cell line. Cytokine, 14: 225-9, 2001.
    OpenUrlCrossRefPubMed
  20. ↵
    Sobhani I, Bado A, Vissuzaine C, et al Leptin secretion and leptin receptor in the human stomach. Gut, 47: 178-83, 2000.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Morash B, Johnstone J, Leopold C, et al The regulation of leptin gene expression in the C6 glioblastoma cell line. Mol Cell Endocrinol, 165: 97-105, 2000.
    OpenUrlCrossRefPubMed
  22. ↵
    Tsuchiya T, Shimizu H, Hori T, Mori M Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol, 365: 273-9, 1999.
    OpenUrlCrossRefPubMed
  23. ↵
    Mix H, Widjaja A, Jandl O, et al Expression of leptin receptor isoforms in the human stomach. Gut, 47: 481-6, 2000.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Hino M, Nakano T, Yamane T, Ohta K, Takubo T, Tatsumi N Leptin receptor and leukemia. Leuk Lymphoma, 36: 457-61, 2000.
    OpenUrlCrossRefPubMed
  25. ↵
    Attoub S, Noe V, Pirola L, et al Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho- and rac-dependent signaling pathways. FASEB J, 14: 2329-38, 2000.
    OpenUrlCrossRefPubMed
  26. ↵
    Isono M, Inoue R, Kamida T, Kobayashi H, Matsuyama J Significance of leptin expression in invasive potential of pituitary adenomas. Clin Neurol Neurosurg, 105: 111-6, 2003.
    OpenUrlCrossRefPubMed
  27. ↵
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348: 1625-38, 2003.
    OpenUrlCrossRefPubMed
  28. ↵
    World Cancer Research Fund. . Food, nutrition and the prevention of cancer: a global perspective, 371-3, American Institute for Cancer Res Washington, D.C. 1997.
  29. ↵
    Carroll K Obesity as a risk factor for certain types of cancer. Lipids, 33: 1055-9, 1998.
    OpenUrlCrossRefPubMed
  30. ↵
    Bergstrom A, Pisani P, Tenet V, Wolk A, Adami H-O Overweight as an avoidable cause of cancer in Europe. Int J Cancer, 92: 927 2001.
    OpenUrlCrossRef
  31. ↵
    Peto J Cancer epidemiology in the last century and the next decade. Nature (Lond), 411: 390-5, 2001.
    OpenUrlCrossRefPubMed
  32. ↵
    Cleary MP, Maihle NJ The rule of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med, 216: 28-43, 1997.
    OpenUrlCrossRefPubMed
  33. ↵
    Willett WC Fat, energy and breast cancer. J Nutr, 127: 921S-3S, 1997.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Galanis DJ, Kolonel LN, Lee J, Le Marchand L Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control, 9: 217-24, 1998.
    OpenUrlCrossRefPubMed
  35. ↵
    Sobin LH Wittekin CH eds. . 1997 UICC TNM classification of malignant tumors, 5th edition John Wiley and Sons, Inc. New York 1997.
  36. ↵
    Tessitore L, Vizio B, Jenkins O, De Stefano I, et al Leptin expression in colorectal and breast cancer patients. Int J Mol Med, 5: 421-6, 2000.
    OpenUrlPubMed
  37. ↵
    Ozet A, Arpaci F, Yilmaz llker M, et al Effect of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol, 31: 424-7, 2001.
    OpenUrlCrossRefPubMed
  38. ↵
    Christo S, Bolhke K, Moschos S, Cramer W Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer, 80: 523-6, 1999.
    OpenUrlCrossRefPubMed
  39. ↵
    Tartaglia LA The leptin receptor. J Biol Chem, 272: 6093-6, 1997.
    OpenUrlFREE Full Text
  40. ↵
    Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J Identification of leptin receptor in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol, 188: 219-26, 2002.
    OpenUrlCrossRefPubMed
  41. ↵
    Hu X, Juneja SC, Maihle NJ, Cleary MP Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst (Bethesda), 94: 1704-11, 2002.
    OpenUrlCrossRefPubMed
  42. ↵
    O’Brien SN, Welter BH, Price TM, Clemson U, Glemson SG Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun, 259: 695-8, 1999.
    OpenUrlCrossRefPubMed
  43. ↵
    Waxler SH, Taber P, Melcher LP Obesity and the time of appearance of spontaneous mammary carcinoma in C3H mice. Cancer Res, 13: 276-8, 1953.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Heston WE, Vlahakis G Genetic obesity and neoplasia. J Natl Cancer Inst (Bethesda), 29: 197-209, 1962.
    OpenUrlPubMed
  45. ↵
    Cleary MP, Phillip FC, Getzin SC, et al Genetically obese MMTV-TGF-alph/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat, 77: 205-15, 2003.
    OpenUrlCrossRefPubMed
  46. ↵
    Islam MS, Sjoholm A, Emilsson V Fetal pancreatic islets express functional leptin receptors and leptin stimulates proliferation of fetal islet cells. Int J Obes Relat Metab Disord, 24: 1246-53, 2000.
    OpenUrlCrossRefPubMed
  47. ↵
    Okumura M, Yamamoto M, Sakuma H, et al Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta, 1592: 107-16, 2002.
    OpenUrlPubMed
  48. ↵
    Onuma M, Bub JD, Rummel TL, Iwamoto Y Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem, 278: 42660-7, 2003.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 293: 622-8, 2002.
    OpenUrlCrossRefPubMed
  50. ↵
    Bischof P Endocrine, paracrine and autocrine regulation of trophoblastic metalloproteinases. Early Pregnancy, 5: 30-1, 2001.
    OpenUrlPubMed
  51. ↵
    Castellucci M, De Matteis R, Meisser A, et al Leptin modulates extracellular matrix molecules and metalloproteinases: possible implications for trophoblast invasion. Mol Hum Reprod, 6: 951-8, 2000.
    OpenUrlCrossRefPubMed
  52. ↵
    Kume K, Satomura K, Nishisho S, et al Potential role of leptin in endochondral ossification. J Histochem Cytochem, 50: 159-69, 2002.
    OpenUrlCrossRefPubMed
  53. ↵
    Kyogoku S, Hirohata T, Takeshita S, Nomura Y, Shigematsu T, Horie A Survival of breast-cancer patients and body size indicators. Int J Cancer, 46: 824-31, 1990.
    OpenUrlCrossRefPubMed
  54. ↵
    Coskun U, Gunel N, Torunner FB, et al Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma, 50: 41-6, 2003.
    OpenUrlPubMed
  55. ↵
    Masuzaki H, Ogawa H, Sagawa N, et al Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med, 3: 1029-33, 1997.
    OpenUrlCrossRefPubMed
  56. ↵
    Sivan E, Whittaker PG, Shiha D, et al Leptin in human pregnancy: the relationship with gestational hormones. Am J Obstet Gynecol, 179: 1128-32, 1998.
    OpenUrlCrossRefPubMed
  57. ↵
    Gavrilova O, Barr V, Marcus-Samuels B, Reitman M Hyperleptinemia of pregnancy associated with the appearance of circulating form of the leptin receptor. J. Biol Chem, 272: 30546-51, 11997
  58. ↵
    Woo JC, Yu T, Hur TC Breast cancer in pregnancy: a literature review. Arch Surg, 138: 91-9, 2003.
    OpenUrlCrossRefPubMed
  59. ↵
    Kuerer HM, Cunningha JD, Brower ST, Tartter PI Breast carcinoma associated with pregnancy and lactation. Surg Oncol, 6: 93-8, 1997.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 10 (13)
July 2004
Volume 10, Issue 13
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer
Makoto Ishikawa, Joji Kitayama and Hirokazu Nagawa
Clin Cancer Res July 1 2004 (10) (13) 4325-4331; DOI: 10.1158/1078-0432.CCR-03-0749

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer
Makoto Ishikawa, Joji Kitayama and Hirokazu Nagawa
Clin Cancer Res July 1 2004 (10) (13) 4325-4331; DOI: 10.1158/1078-0432.CCR-03-0749
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Featured Articles

  • Differential Effects of Delivery of Omega-3 Fatty Acids to Human Cancer Cells by Low-Density Lipoproteins versus Albumin
  • Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells
  • Functionalization of Tumor Necrosis Factor-α Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window
Show more Featured Articles

Molecular Oncology, Markers, Clinical Correlates

  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
  • Transcription Factor AP-2γ Is a Developmentally Regulated Marker of Testicular Carcinoma In situ and Germ Cell Tumors
  • Flt-4–Positive Endothelial Cell Density and Its Clinical Significance in Non–Small Cell Lung Cancer
Show more Molecular Oncology, Markers, Clinical Correlates
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement